» Articles » PMID: 28704967

Variability in DNA Repair Capacity Levels Among Molecular Breast Cancer Subtypes: Triple Negative Breast Cancer Shows Lowest Repair

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2017 Jul 15
PMID 28704967
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer (BC) is a heterogeneous disease which many studies have classified in at least four molecular subtypes: Luminal A, Luminal B, HER2-Enriched, and Basal-like (including triple-negative breast cancer, TNBC). These subtypes provide information to stratify patients for better prognostic predictions and treatment selection. Individuals vary in their sensitivities to carcinogens due to differences in their DNA repair capacity (DRC) levels. Although our previous case-control study established low DRC (in terms of NER pathway) as a BC risk factor, we aim to study this effect among the molecular subtypes. Therefore, the objectives of this study include investigating whether DRC varies among molecular subtypes and testing any association regarding DRC. This study comprised 267 recently diagnosed women with BC (cases) and 682 without BC (controls). Our results show a substantial variability in DRC among the molecular subtypes, with TNBC cases ( = 47) having the lowest DRC (-value < 0.05). Almost 80 percent of BC cases had a DRC below the median (4.3%). Low DRC was strongly associated with the TNBC subtype (OR 7.2; 95% CI 3.3, 15.7). In conclusion, our study provides the first report on the variability among the molecular subtypes and provides a hypothesis based on DRC levels for the poor prognosis of TNBC.

Citing Articles

DNA Repair Capacity and Clinicopathological Characteristics in Puerto Rican Hispanic/Latino Patients with Metastatic Castration-Resistant Prostate Cancer.

Matta J, Ortiz-Sanchez C, Encarnacion-Medina J, Torres-Caraballo S, Oliveras J, Park J Cancers (Basel). 2025; 17(2).

PMID: 39858060 PMC: 11763443. DOI: 10.3390/cancers17020279.


miR-186-ANXA9 signaling inhibits tumorigenesis in breast cancer.

Wang Z, Zhou X, Deng X, Ye D, Liu D, Zhou B Front Oncol. 2023; 13:1166666.

PMID: 37841425 PMC: 10570552. DOI: 10.3389/fonc.2023.1166666.


The Unique Spectrum of Germline Mutations in Colombian Patients with Extracolonic Carcinomas.

Rodriguez-Rojas L, Candelo E, Pachajoa H, Garcia-Robledo J, Nastasi-Catanese J, Olave-Rodriguez J Appl Clin Genet. 2023; 16:53-62.

PMID: 37096204 PMC: 10122495. DOI: 10.2147/TACG.S370416.


Association between DNA repair capacity and body mass index in women.

Crespo-Orta I, Ortiz C, Encarnacion J, Suarez E, Matta J Mutat Res. 2023; 826:111813.

PMID: 36621052 PMC: 10200731. DOI: 10.1016/j.mrfmmm.2022.111813.


TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.

Liu Q, Chung S, Murata M, Han B, Gao B, Zhang M Int J Biol Sci. 2022; 18(10):4203-4218.

PMID: 35844787 PMC: 9274500. DOI: 10.7150/ijbs.70583.


References
1.
Alexander B, Sprott K, Farrow D, Wang X, DAndrea A, Schnitt S . DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin Cancer Res. 2010; 16(23):5796-804. PMC: 4220607. DOI: 10.1158/1078-0432.CCR-10-0292. View

2.
Gaudet M, Press M, Haile R, Lynch C, Glaser S, Schildkraut J . Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat. 2011; 130(2):587-97. PMC: 3721192. DOI: 10.1007/s10549-011-1616-x. View

3.
Ribeiro E, Ganzinelli M, Andreis D, Bertoni R, Giardini R, Fox S . Triple negative breast cancers have a reduced expression of DNA repair genes. PLoS One. 2013; 8(6):e66243. PMC: 3692506. DOI: 10.1371/journal.pone.0066243. View

4.
Partridge A, Rumble R, Carey L, Come S, Davidson N, Di Leo A . Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014; 32(29):3307-29. PMC: 6076042. DOI: 10.1200/JCO.2014.56.7479. View

5.
Pal S, Luchtenborg M, Davies E, Jack R . The treatment and survival of patients with triple negative breast cancer in a London population. Springerplus. 2014; 3:553. PMC: 4188837. DOI: 10.1186/2193-1801-3-553. View